Recently, the decline in mortality for lung cancer, especially NSCLC, has accelerated [1,2] owing to therapeutic advances, including immunotherapy (i.e., inhibitors of programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-L1)) and molecular targeted therapy. The gene discussed is PDCD1; the disease is lung cancer.